s request. The peptides are bi-weekly injected. When adverse effects would be observed, the interval of vaccination and the doses of peptides could be modified.
Sponsors
Kurume University Research Center for Innovative Cancer Therapy, Clinical Research Division, Department of Immunology, Kurume University School of medicine
Conditions
Prostate cancermalignant glioma (glioblastoma)
Phase 2
Phase II clinical trial of personalized peptide vaccination for decetaxel no indicated patients with hormone-refractory prostate cancer
Active, not recruitingJPRN-UMIN000001242
Start: 2009-04-01Target: 55Updated: 2026-06-29
Phase II clinical trial of personalized peptide vaccination for standard therapy failure patients with malignant glioma (glioblastoma)
Active, not recruitingJPRN-UMIN000001243
Start: 2009-04-01Target: 40Updated: 2026-06-29